Leading all biotech initial public offerings conducted this year in the U.S., Coley Pharmaceutical Group Inc. topped the list with proceeds of $96 million, then raised another $10 million through a concurrent private placement with Pfizer Inc.(BioWorld Today)
Two months ago, when Anadys Pharmaceuticals Inc. signed what might be the largest Phase I deal in biotech history, the company's CEO said Anadys wouldn't need to do a financing for at least two years. (BioWorld Today)
Inching closer to a market that, until recently, was virtually untapped, XenoPort Inc. proved in a Phase IIb trial that its restless leg syndrome candidate, XP13512, was significantly better than placebo in relieving patient symptoms. (Bioworld Today)
In order to grow in the area of proteomics, Invitrogen Corp. signed a definitive agreement to acquire BioSource International Inc. for about $130 million in cash. (BioWorld Today)
Millennium Pharmaceuticals Inc. restructured its collaboration for Integrilin, granting exclusive U.S. development and commercialization rights to Schering-Plough Corp. and trading its profit-sharing arrangement for a significant royalty and up to $85.5 million in payments. (BioWorld Today)
In what historically might be one of Amgen Inc.'s top quarters, the company posted earnings per share of 88 cents and a net income of $1.1 billion, significantly exceeding consensus estimates and driving the company's stock up 15.1 percent. (BioWorld Today)
